Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Express Scripts
McKinsey
Baxter
Mallinckrodt

Last Updated: November 28, 2022

Details for Patent: 6,555,581


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,555,581 protect, and when does it expire?

Patent 6,555,581 protects LEVOXYL and is included in one NDA.

This patent has twenty-six patent family members in nine countries.

Summary for Patent: 6,555,581
Title: Levothyroxine compositions and methods
Abstract:The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
Inventor(s): Franz; G. Andrew (St. Louis, MO), Strauss; Elaine A. (Seminole, FL), DiMenna; Philip A. (St. Petersburg, FL), Gemma; Rocco L. (Dover, OH)
Assignee: Jones Pharma, Inc. (St. Petersburg, FL)
Application Number:10/077,677
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Drugs Protected by US Patent 6,555,581

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-001 May 25, 2001 AB1,AB3 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-002 May 25, 2001 AB1,AB3 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-003 May 25, 2001 AB1,AB3 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-004 May 25, 2001 AB1,AB3 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,555,581

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002240394 See Plans and Pricing
Australia 2002258397 See Plans and Pricing
Australia 2002332507 See Plans and Pricing
Australia 2002341555 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Boehringer Ingelheim
Mallinckrodt
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.